Current Status and Perspectives in Stem Cell Therapy for Heart.

Fen-Chiung Lin, Wen-Pin Chen, Pao-Hsien Chu, Kou-Gi Shyu, Ming-Shien Wen

Abstract readReview

In one paragraph

Review in Acta Cardiologica Sinica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fen-Chiung LinGraduate Institute of Clinical Medicine, Taipei Medical University; ; Division of Cardiology, Linkou Chang Gung Memorial Hospital; ; College of Medicine, Chung Gung University, Taoyuan, Taiwan.

Wen-Pin ChenGraduate Institute of Clinical Medicine, Taipei Medical University; ; Graduate Institute of Pharmacology, National Taiwan University, Taipei;

Pao-Hsien ChuDivision of Cardiology, Linkou Chang Gung Memorial Hospital; ; College of Medicine, Chung Gung University, Taoyuan, Taiwan.

Kou-Gi ShyuGraduate Institute of Clinical Medicine, Taipei Medical University;

Ming-Shien WenDivision of Cardiology, Linkou Chang Gung Memorial Hospital; ; College of Medicine, Chung Gung University, Taoyuan, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledFor most patients, the prognosis of heart failure remains poor despite therapeutic advancement in recent decades. The option of cardiac transplantation is high risk and limited by a shortage of donors. Traditionally, the heart had been considered a terminally differentiated organ incapable of regeneration. However, numerous preclinical and clinical studies have been performed since the first report of cell therapy in heart failure using skeletal myoblasts in 2001. These investigations looked at the promising potential and use of several kinds of stem cells, which could some day dramatically alter the understanding of the regenerative capacity of the heart. To date, although there is no existing cardiac cell therapy that has been conclusively reported to be effective, stem cell-related cardiomyocyte regeneration strategies have become significant areas of research in modern cardiovascular medicine. In this review, we outline a variety of common cell sources, surface biomarkers of stem cells, and provide information related to cardiac cell therapy clinical trials. KEY WORDS: Clinical trial; Stem cell.

Identifiers

PMID27122815

PMCPMC4834955

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.